OmniAb Q1 2023 revenue $16.9M, net loss $6.1M; 301 active partner programs

OmniAb, Inc.

2023-Q1 EPS reported -$0.06 revenue$16,919,000

Revenue $16.9M, up from $9.6M YoY, driven by $10.0M milestone from TECVAYLI EU commercial sale.
Net loss $6.1M ($0.06/share) vs $6.3M ($0.08/share) YoY; cash & investments $113.6M.
301 active programs, 27 in clinical/commercial; new license with Neurocrine Biosciences post-quarter.
Introduced OmniDeep in silico platform; Seagen's SGN-BB228 entered Phase 1 for melanoma.
Immunovant expects Phase 2 Graves' disease results H2 2023; CStone sBLA for sugemalimab in ESCC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OmniAb, Inc. reported the three months ended March 31, 2023 results: revenue $16.9 million, net income $6.1 million, EPS $0.06 per share.

Period: the three months ended March 31, 2023
Revenue: $16.9 million
Net income: $6.1 million
EPS: $0.06 per share
Result: reported results

Exact text from the filing

Revenue for the first quarter of 2023 was $16.9 million, compared with $9.6 million for the same period in 2022, with the increase primarily due to the recognition of a $10.0 million milestone payment related to the first commercial sale of TECVAYLI® (teclistamab) in the European Union. Research and development expense was $13.8 million for the first quarter of 2023, compared with $10.8 million for the same period in 2022, with the increase primarily due to investments in facilities, headcount and technology innovation. General and administrative expense was $8.2 million for the first quarter of 2023, compared with $4.1 million for the same period in 2022, with the increase primarily due to higher headcount and other expenses related to being an independent publicly traded company. Net loss for the first quarter of 2023 was $6.1 million, or $0.06 per share, compared with a net loss of $6.3 million, or $0.08 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

OmniAb, Inc. filing history →

Source: SEC EDGAR

accession 0001846253-23-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.